• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 29, 2022
Product Development

Jan. 28 Quick Takes: Lilly halts Olumiant in lupus, portends rejection in atopic dermatitis

Plus Regeneron, Sanofi withdraw Libtayo sBLA and updates from TG, Novavax and more
Read More
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

Novo’s semaglutide to test metabolic, neuroprotective mechanism; AB Science’s masitinib is testing neuroinflammatory hypothesis
Read More
BioCentury | Dec 16, 2020
Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

Cancer screening play Singlera raises megaroundSinglera Genomics Inc. raised $150 million in a series B round led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and
Read More
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Why modulating microglia could give drug developers a new handle on neurodegeneration
Read More
BioCentury | Jun 15, 2018
Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

Read More
BioCentury | Apr 13, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

Read More
BioCentury | Apr 9, 2018
Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

Read More
BioCentury | Jun 9, 2017
Clinical News

vTv completes enrollment in Phase III of RAGE antagonist for AD

Read More
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

Read More
BioCentury | Aug 1, 2016
Clinical News

Azeliragon: Additional Phase IIb data

Read More
Items per page:
1 - 10 of 12
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa